A phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma

• Main Authors: Choo, S. P., Chowbay, B., Ng, Q. S., Thng, C. H., Lim, Cindy., Hartono, Septian., Koh, T. S., Huynh, H., Poon, D., Ang, M. K., Chang, S., Toh, H. C.
• 其他作者: School of Electrical and Electronic Engineering
• 格式: Article
• 語言: English
• 出版: 2013
• 在線閱讀: https://hdl.handle.net/10356/106813; http://hdl.handle.net/10220/17665; http://dx.doi.org/10.1016/j.ejca.2012.11.008
• 機構: Nanyang Technological University

Background & Aims Preclinical studies have demonstrated the additive effect of rapamycin with bevacizumab for hepatocellular carcinoma treatment. We conducted a Phase 1 study to evaluate the safety and pharmacokinetics of the combination in patients with hepatocellular carcinoma. Methods...